We here at HQI are excited about the year ahead and continuing the collaborative work of enhancing patient safety and fostering a culture of excellence within hospitals. Our role is to support our members’ efforts toward providing the safest and highest quality care possible through education and the sharing of information and resources.
In this edition of Quality Quarterly, we share updates on enrollment in, and usage of, HQI’s Hospital Quality Improvement Platform (HQIP). We also explore possible emerging side effects of popular weight loss drugs like Ozempic and Wegovy and why anaphylactic shock is a growing concern in hospitals, and we examine the relationship between hospital sepsis bundle compliance and sepsis mortality rates.
There is more to come from HQI in 2025 with new initiatives to further elevate patient safety standards. We’re working through HQIP to support hospitals in complying with Assembly Bill 1204, which mandates the creation and publication of equity reports and plans by Sept. 30, 2025. To help ease the burden of reporting, HQIP will be able to generate stratified and pre-filled equity reports for hospitals.
Further, in response to the new 2025 Patient Safety Structural Measure from the Center for Medicare & Medicaid Services (CMS), HQI is offering support to hospitals in meeting these requirements through HQI Cares: Implementing BETA HEART® and our federal PSO Collaborative Healthcare Patient Safety Organization. Hospitals will be guided through proven strategies and practices that support systemic and cultural improvements in safety to meet CMS goals.
We’re pleased to share this information with you, and we look forward to further collaborations and conversations in the year ahead to achieve new milestones in patient safety and quality care.